Phase III Clinical Efficacy (n=324): 82% reduction in severe glabellar lines at 30 days post-administration.

Pharmacodynamics: Initial onset 48-72 hours. Peak therapeutic effect at 14 days. Sustained denervation duration: 12-16 weeks.

Excipients: 0.5mg Human Serum Albumin (HSA), 0.9mg Sodium Chloride.

RECONSTITUTION

Vacuum-dried lyophilized powder. Inject 2.5mL sterile, preservative-free 0.9% Sodium Chloride into the 100U vial. Yields a concentration of 4U per 0.1mL. Rotate gently; do not agitate.

STABILITY PROTOCOL

Unopened shelf life: 36 months when stored at 2-8°C. Post-reconstitution: Administer within 24 hours. Must maintain continuous 2-8°C cold chain during transport and storage.

Strictly for administration by certified medical practitioners. Contraindicated in individuals diagnosed with Amyotrophic Lateral Sclerosis (ALS), Myasthenia Gravis, or Lambert-Eaton syndrome. Absolute maximum cumulative dosage is 300U within a 90-day biological period. Clinical outcomes vary ±15% dependent on regional muscle mass and precise injection depth.